


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula



(I)

wherein

m is 0, 1, 2, 3 or 4;

each R^1 independently represents halogen, cyano, hydroxyl, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylsulphonyl or sulphonamido ($-SO_2NH_2$);

X represents a bond or $-CH_2-$ and Y represents a bond or $-CH_2-$, provided that X and Y do not both simultaneously represent a bond or $-CH_2-$;

n is 0, 1 or 2;

each R^2 independently represents halogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl ;

q is 0 or 1;

p is 0, 1 or 2;

R^3 represents a group selected from halogen, NR^6R^7 , carboxyl or C_1 - C_6 alkyl wherein said C_1 - C_6 alkyl group is optionally substituted by one or more halogen, amino, hydroxyl, C_1 - C_6 alkoxy, N -(C_1 - C_6 alkyl)amino, N,N -di-(C_1 - C_6 alkyl)amino, carboxy or carbamoyl;

R^4 represents hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl or halogen;

t is 0, 1 or 2, provided that p and t are not both 0;

R^5 represents a saturated or unsaturated 5- to 10-membered ring system which ring system may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, nitro, hydroxyl, carboxyl, $-C(O)H$, $-NR^8R^9$, $-C(O)NR^{10}R^{11}$, $-NHC(O)R^{12}$, $-NHSO_2R^{13}$, $-SO_2NR^{14}R^{15}$, $-NHC(O)NR^{16}R^{17}$, a group selected from

C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio,

C_1 - C_6 alkylsulphonyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkylcarbonyl, phenylcarbonyl, C_3 - C_6

cycloalkyl, , phenyl and a saturated or unsaturated 5- to 6-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally substituted by one or more substituents independently selected from halogen, cyano, hydroxyl, carboxyl, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy and C_1 - C_6 alkoxycarbonyl;

R^6 and R^7 each independently represent hydrogen or a group selected from C_1 - C_6 alkyl and C_1 - C_6 alkylcarbonyl, each of which may be optionally substituted by one or more substituents selected from halogen, amino, hydroxyl, C_1 - C_6 alkoxy, N -(C_1 - C_6 alkyl)amino, N,N -di-(C_1 - C_6 alkyl)amino, carboxy, carbamoyl or C_1 - C_6 alkoxycarbonyl, or R^6 and R^7 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted by one or more substituent selected from halogen, amino, hydroxyl, C_1 - C_6 alkoxy, N -(C_1 - C_6 alkyl)amino, N,N -di-(C_1 - C_6 alkyl)amino, carboxy, carbamoyl or C_1 - C_6 alkoxycarbonyl ;

R^8 , R^9 , R^{10} , R^{11} each independently represent hydrogen or a group selected from C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, each group being optionally substituted by one or more substituents independently selected from halogen, amino, hydroxyl, C_1 - C_6 alkoxy, N -(C_1 - C_6 alkyl)amino, N,N -di-(C_1 - C_6 alkyl)amino, carboxy or carbamoyl; or R^{10} and R^{11} , together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one substituent selected from halogen, amino, hydroxyl, C_1 - C_6 alkoxy, N -(C_1 - C_6 alkyl)amino, N,N -di-(C_1 - C_6 alkyl)amino, carboxy or carbamoyl;

R^{12} represents hydrogen or a group selected from C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, each group being optionally substituted by one or more substituents independently selected from halogen, amino, hydroxyl, C_1 - C_6 alkoxy, N -(C_1 - C_6 alkyl)amino, N,N -di-(C_1 - C_6 alkyl)amino, carboxy or carbamoyl;

R^{13} represents a group selected from C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, each group being optionally substituted by one or more substituents independently selected from halogen, amino, hydroxyl, C_1 - C_6 alkoxy, N -(C_1 - C_6 alkyl)amino, N,N -di-(C_1 - C_6 alkyl)amino, carboxy or carbamoyl;

R^{14} , R^{15} , R^{16} and R^{17} each independently represent hydrogen or a group selected from C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, each group being optionally substituted by one or more substituents independently selected from halogen, amino, hydroxyl, C_1 - C_6 alkoxy, N -(C_1 - C_6 alkyl)amino, N,N -di-(C_1 - C_6 alkyl)amino, carboxy or carbamoyl; or R^{14} and R^{15} , or R^{16} and R^{17} , together with the nitrogen atom to which they are attached each independently form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one substituent selected from halogen, amino, hydroxyl, C_1 - C_6 alkoxy, N -(C_1 - C_6 alkyl)amino, N,N -di-(C_1 - C_6 alkyl)amino, carboxy or carbamoyl;

or a pharmaceutically acceptable salt or solvate thereof.

2. (Original) A compound according to claim 1 wherein X represents a bond and Y represents $\text{---CH}_2\text{---}$.
3. (Currently amended) A compound according to claim 1 ~~or claim 2~~ wherein q is 1.
4. (Currently amended) A compound according to ~~any one of claims 1 to 3~~ claim 1 wherein m is 0 or 1 and R^1 represents halogen.
5. (Currently amended) A compound according to ~~any one of claims 1 to 4~~ claim 1 wherein n is 0.
6. (Currently amended) A compound according to ~~any one of claims 1 to 5~~ claim 1 wherein R^3 represents halogen, $\text{---NR}^6\text{R}^7$ or $\text{C}_1\text{---C}_6$ alkyl optionally substituted by one or two substituents selected from halogen, amino or hydroxyl
7. (Currently amended) A compound according to ~~any one of claims 1 to 6~~ claim 1 wherein R^4 represents hydrogen.
8. (Currently amended) A compound according to ~~any one of claims 1 to 7~~ claim 1 wherein R^5 represents a saturated or unsaturated 5- to 10-membered ring system which ring system may comprise one, two, three or four ring heteroatoms independently selected from nitrogen, oxygen and sulphur and which may be optionally substituted one two or three substituents independently selected from halogen, cyano, oxo, nitro, hydroxyl, carboxyl, ---C(O)H , $\text{---NR}^8\text{R}^9$, $\text{---C(O)NR}^{10}\text{R}^{11}$, ---NHC(O)R^{12} , $\text{---NHSO}_2\text{R}^{13}$, $\text{---SO}_2\text{NR}^{14}\text{R}^{15}$, $\text{---NHC(O)NR}^{16}\text{R}^{17}$, a group selected from $\text{C}_1\text{---C}_6$ alkyl, $\text{C}_2\text{---C}_6$ alkenyl, $\text{C}_2\text{---C}_6$ alkynyl, $\text{C}_1\text{---C}_6$ alkoxy, $\text{C}_1\text{---C}_6$ alkylthio, $\text{C}_1\text{---C}_6$ alkylsulphonyl, $\text{C}_1\text{---C}_6$ haloalkyl, $\text{C}_1\text{---C}_6$ alkylcarbonyl, phenylcarbonyl, $\text{C}_3\text{---C}_6$ cycloalkyl, , phenyl and a saturated or unsaturated 5- to 6-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group

being optionally substituted by one or more substituents independently selected from halogen, cyano, hydroxyl, carboxyl, C₁-C₆ alkyl, C₁-C₆ cycloalkyl, C₁-C₆ alkoxy and C₁-C₆ alkoxycarbonyl.

9. (Currently amended) A claim according to ~~any one of claims 4 to 8~~ claim 1 wherein R⁵ represents phenyl, wherein said phenyl is optionally substituted with one or two substituents independently selected from -NHC(O)R¹², -NHC(O)NR¹⁶R¹⁷, hydroxyl or C₁-C₆ alkoxy, or wherein said phenyl is optionally substituted with one, two or three substituents independently selected from halogen, hydroxyl, or carboxyl.

10. (Original) A compound according to claim 1 selected from:

N-(2-([(2*S*)-2-amino-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy)-4-methoxyphenyl)acetamide;

N-(2-([(2*S*)-2-amino-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy)-4-hydroxyphenyl)acetamide bis(trifluoroacetate) (salt);

N-(2-([(2*S*)-2-amino-3-(5-fluoro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy)-4-methoxyphenyl)acetamide;

N-(2-([(2*S*)-2-amino-3-(5-fluoro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy)-4-hydroxyphenyl)acetamide bis(trifluoroacetate) (salt) ;

N-(2-([(2*S*)-2-Amino-3-(1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy)-4-methoxyphenyl)acetamide;

N-(2-([(2*S*)-2-Amino-3-(1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy)-4-hydroxyphenyl)acetamide bis(trifluoroacetate) (salt);

N-(2-([(2*S*)-2-(Acetylamino)-3-(5-fluoro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy)-4-methoxyphenyl)acetamide ;

N-(2-[3-Amino-2-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl)acetamide bis(trifluoroacetate);

N-(2-[3-Amino-2-(5-fluoro-1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl) acetamide bis(trifluoroacetate);

N-(2-[3-Amino-2-(1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl) acetamide bis(trifluoroacetate);

N-(2-[3-Amino-2-(5-chloro-1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]phenyl) urea bis(trifluoroacetate);

N-(2-[3-Amino-2-(5-fluoro-1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]phenyl) urea bis(trifluoroacetate);

N-(2-[2-Chloro-3-(5-chloro-1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-hydroxyphenyl) acetamide trifluoroacetate (salt);

N-(2-[2-(5-Chloro-1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl) acetamide trifluoroacetate;

5-(((2*S*)-2-Amino-3-(5-fluoro-1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl)oxy)-2*H*-1,4-benzoxazin-3(4*H*)-one;

8-(((2*S*)-2-Amino-3-(5-fluoro-1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl)oxy)quinolin-2(1*H*)-one;

5-Chloro-2-[2-chloro-3-(5-chloro-1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-hydroxybenzoic acid;

2-[2-Amino-3-(5-chloro-1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-5-chloro-4-hydroxybenzoic acid;


5-chloro-2-[3-(5-chloro-1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-(methylamino)propoxy]-4-hydroxybenzoic acid;

5-chloro-2-[3-(5-chloro-1'*H*,3'*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-(dimethylamino)propoxy]-4-hydroxybenzoic acid

and pharmaceutically acceptable salts and solvates of any one thereof.


11. (Original) A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof which comprises:

(a) converting a compound of formula (II)




wherein R^1 , m , X , Y , R^2 , n , q , p , R^4 , t and R^5 are as defined in formula (I), into a compound of formula (I); or

(b) reacting a compound of formula (III)




wherein R^1 , m , X , y , R^2 , n and q are as defined for formula (I), with a compound of formula (IV)



wherein L is a leaving group and p , R^3 , R^4 , t and R^5 are as defined for formula (I);

(c) reacting a compound of formula (V)



wherein R^1 , m , X , Y , R^2 , n , q , p , R^3 , R^4 and t are as defined for formula (I), with a compound of formula (VI)



wherein L is a leaving group and R^5 is as defined for formula (I);

and optionally thereafter if necessary:

- (i) converting a compound of formula(I) into another compound of formula (I);
- (ii) removing any protecting groups; or
- (iii) forming a pharmaceutically acceptable salt or solvate.

12. (Currently amended) A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 10~~ claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

13. (Currently amended) A process for the preparation of a pharmaceutical composition as ~~claimed in claim 12 which comprises~~ comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1, in association with a pharmaceutically acceptable adjuvant, diluent or carrier, the process comprising mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof ~~as claimed in any one of claims 1 to 10~~ with a pharmaceutically acceptable adjuvant, diluent or carrier.

14. (Cancelled)

15. (Currently amended) A method of treating a human disease or condition in which modulation of chemokine receptor activity is beneficial, the method comprising administering to a patient in need thereof a therapeutically effective amount Use-of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 10 claim~~ 1 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

16. (Currently amended) A method of treating rheumatoid arthritis, the method comprising administering to a patient in need thereof a therapeutically effective amount Use-of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 10 claim~~ 1 in the manufacture of a medicament for use in treating rheumatoid arthritis.

17. (Currently amended) A method of treating chronic obstructive pulmonary disease, the method comprising administering to a patient in need thereof a therapeutically effective amount Use-of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 10 claim~~ 1 in the manufacture of a medicament for use in treating chronic obstructive pulmonary disease.

18. (Currently amended) A method of treating asthma, the method comprising administering to a patient in need thereof a therapeutically effective amount Use-of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 10 claim~~ 1 in the manufacture of a medicament for use in treating asthma.

19. (Currently amended) A method of treating multiple sclerosis, the method comprising administering to a patient in need thereof a therapeutically effective amount Use-of a compound

of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 10~~ claim 1 in the manufacture of a medicament for use in treating multiple sclerosis.

20. (Currently amended) A method of treating an inflammatory disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 10~~ claim 1.

21. (Currently amended) A method of treating an airways disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 10~~ claim 1.